WEST PHARMACEUTICAL SERVICES INC 8-K

What Happened
On July 23, 2026 West Pharmaceutical Services, Inc. announced its second-quarter 2026 financial results and filed a Form 8-K reporting that release (Item 2.02). The 8-K attaches the company press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2), and includes a Regulation FD disclosure (Item 7.01). The report was signed by Robert W. McMahon, Senior Vice President and Chief Financial Officer, on July 23, 2026. The body of the 8-K references the Q2 results; the detailed financials are provided in the attached exhibits.

Key Details

• Filing date: July 23, 2026 (Form 8-K).
• Item 2.02: Announced second-quarter 2026 financial results (press release attached as Exhibit 99.1).
• Exhibit 99.2: Investor presentation dated July 23, 2026 accompanying the release.
• Item 7.01: Regulation FD disclosure was made (ensures material info was publicly shared).
• Filing signed by Robert W. McMahon, SVP & CFO; Exhibit 104 includes the Inline XBRL cover page.

Why It Matters
Earnings releases (quarterly results) are material events that can affect the stock price and investors’ view of company performance. This 8-K signals that West has publicly disclosed its Q2 2026 results and provided a presentation for investors — review the attached press release and presentation for revenue, earnings per share, guidance, and segment or operational details. The Regulation FD disclosure indicates the company made the information available broadly and simultaneously.